Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions

Michael V. Rocco^a Arlene Chapman^b Glenn M. Chertow^c Debbie Cohen^d
Jing Chen^e Jeffrey A. Cutler^f Matthew J. Diamond^g Barry I. Freedman^a
Amret Hawfield^a Eric Judd^h Anthony A. Killeen^j Kent Kirchnerⁱ
Cora E. Lewis^h Nicholas M. Pajewski^a Barry M. Wall^k Jerry Yee^l for the
SPRINT Research Group

^aWake Forest School of Medicine, Winston-Salem, N.C., ^bUniversity of Chicago, Chicago, Ill., ^cStanford University School of Medicine, Palo Alto, Calif., ^dPerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa., ^eTulane University School of Medicine, New Orleans, La., and ^fNational Heart, Lung, and Blood Institute, Bethesda, Md., ^gThe Medical College of Georgia at Augusta, Augusta, Ga., ^hUniversity of Alabama at Birmingham, Birmingham, Ala., ⁱVeterans Affairs Medical Center, and University of Mississippi School of Medicine, Jackson, Miss., ^jUniversity of Minnesota, Minneapolis, Minn., ^kUniversity of Tennessee Center for Health Sciences and Veterans Affairs Medical Center, Memphis, Tenn., and ^lHenry Ford Health System, Detroit, Mich., USA

Key Words

Chronic kidney disease · Modification of Diet in Renal Disease study equation · CKD-Epidemiology Collaboration equation · Hypertension · Elderly · Cardiovascular disease · Clinical trial

Abstract

Background: Interventional trials have used either the Modification of Diet in Renal Disease (MDRD) or chronic kidney disease (CKD)-Epidemiology Collaboration (CKD-EPI) equation for determination of estimated glomerular filtration rate (eGFR) to define whether participants have stages 3–5 CKD. The equation used to calculate eGFR may influence the number and characteristics of participants designated as having

CKD. **Methods:** We examined the classification of CKD at baseline using both equations in the Systolic Blood Pressure Intervention Trial (SPRINT). eGFR was calculated at baseline using fasting serum creatinine values from a central laboratory. **Results:** Among 9,308 participants with baseline CKD classification using the 4-variable MDRD equation specified in the SPRINT protocol, 681 (7.3%) participants were reclassified to a less advanced CKD stage (higher eGFR) and 346 (3.7%) were reclassified to a more advanced CKD stage (lower eGFR) when the CKD-EPI equation was used to calculate eGFR. For eGFRs <90 ml/min/1.73 m², participants <75 years were more likely to be reclassified to a less advanced CKD stage; this reclassification was more likely to occur in non-blacks rather than blacks. Participants aged ≥75 years were more likely to be reclassified to a more advanced than a less

advanced CKD stage, regardless of baseline CKD stage. Reclassification of baseline CKD status (eGFR <60 ml/min/1.73 m²) occurred in 3% of participants. **Conclusions:** Use of the MDRD equation led to a higher percentage of participants being classified as having CKD stages 3–4. Younger and non-black participants were more likely to be reclassified as not having CKD using the CKD-EPI equation.

© 2016 S. Karger AG, Basel

Background

The Systolic Blood Pressure Intervention Trial (SPRINT) trial is a National Institutes of Health (NIH)-sponsored trial of blood pressure (BP) control in people without diabetes mellitus at increased risk of developing cardiovascular disease (CVD) [1]. Three specific subgroups were targeted for recruitment due to their increased risk of CVD, including those with prior CV events, age ≥75 years and the presence of stages 3–4 chronic kidney disease (CKD). Accurate classification of CKD will be important for analytic purposes because many of the primary and secondary outcomes will be analyzed by subgroup, including CKD status. During protocol development, the abbreviated (4-variable) Modification of Diet in Renal Disease (MDRD) study equation [2] was chosen to assess for the presence or absence of CKD. Since then, the CKD-Epidemiology Collaboration (CKD-EPI) equation [3] has been developed and deemed acceptable, if not preferred method, for estimating glomerular filtration rate (GFR). Other investigators have reported variability in the classification of CKD stages based on age and other clinical characteristics of study participants [4–11]. To our knowledge, no published analysis has determined the potential impact of applying alternatively estimated GFR (eGFR) equations on defining the presence of CKD in a randomized clinical trial. We hypothesize that some participants who would be classified as having CKD using the MDRD equation would not be found to have CKD if eGFR were calculated using the CKD-EPI equation. In this analysis, we determine the degree of reclassification of CKD stage and identify participant characteristics associated with reclassification.

Methods

Study Sample

SPRINT is a multicenter, randomized clinical trial of standard versus more intensive BP control in participants aged ≥50 years with a heightened risk of CVD, including subgroups of prior CV

events, ≥75 years and/or the presence of CKD. Details of the intervention and outcomes have been previously published [1, 12]. Exclusion criteria included an eGFR <20 ml/min/1.73 m² at baseline by the MDRD equation, diabetes mellitus, prior stroke, polycystic kidney disease and moderate- to high-grade proteinuria (>1,000 mg/day) or albuminuria (>600 mg/day). Participants were randomized to a systolic BP target of either <140 mm Hg (standard arm) or <120 mm Hg (intensive arm). The primary composite end point, including adjudicated CV death, or first myocardial infarction (MI), stroke, heart failure and non-MI acute coronary syndrome was ascertained over a follow-up period of up to 6 years. The intervention was to be assessed in predefined subgroups, including participants with and without CKD (eGFR 20–<60 ml/min/1.73 m² as calculated by the 4-variable MDRD equation) and participants aged <75 or ≥75 years at baseline. There were several key secondary outcomes including, in the CKD subgroup, the rate of end-stage kidney disease (ESKD) or a 50% decline from baseline eGFR, and in the non-CKD subgroup, a 30% decrease from baseline eGFR with an end value of <60 ml/min/1.73 m². Participant selection occurred across the United States with 102 clinical sites in the United States, including Puerto Rico. Written informed consent was obtained from all participants.

Study Measurements

Standardized questionnaires were completed during screening in order to characterize participants based on socioeconomic factors. Self-reported race/ethnicity was categorized as white, black or other and Hispanic or non-Hispanic. The Framingham Risk Score (FRS) for 10-year CVD risk of ≥15% was calculated using lipid values assessed in the previous 12 months [13]. The occurrence of cardiovascular and peripheral arterial events during the previous 10 years was obtained at baseline from patient history and a review of medical records. BP was measured at baseline using a standardized protocol. A central laboratory performed all blood and urine laboratory determinations. Participants were asked to fast for ≥8 h on the day that the blood was collected.

The SPRINT Central Lab measured creatinine in serum and urine on a Roche Chemistry Analyzers (Roche Diagnostics Corporation, Indianapolis, Ind., USA) using a creatinase enzymatic method with calibration traceable to an isotope dilution mass spectrometry (IDMS) procedure. Urine albumin was measured by nephelometry using the Siemens ProSpec nephelometer and a rabbit-derived anti-human albumin antibody. The urine albumin/creatinine ratio (UACR) was calculated using a spot urine sample obtained at the baseline visit and measured in milligrams of albumin per gram of creatinine (mg/g). Baseline eGFR in ml/min/1.73 m² was calculated by the 4-variable MDRD equation using the serum creatinine concentration obtained at the baseline visit. CKD categories were defined using Kidney Disease Improving Global Outcomes guidelines, with the proviso that CKD classification was based on a single determination of eGFR [14].

Statistical Analysis

For both the MDRD and CKD-EPI study equations, eGFR was categorized as ≥90, 60–89, 45–59, 30–44 and 15–29 ml/min/1.73 m². Baseline characteristics of the SPRINT cohort were then compared by reclassification status based on the CKD-EPI equation (reclassified to a less advanced CKD stage (higher eGFR), not reclassified or reclassified to a more advanced CKD stage (lower eGFR) using (as appropriate) analysis of variance/Kruskal–Wallis tests for con-

tinuous variables and chi-square tests/Fisher's exact tests for categorical variables). Based on the 5×5 cross-tabulation of eGFR categories, agreement was also assessed using kappa statistics with Fleiss-Cohen weights [15]. Of the 9,361 participants randomized, there were 53 participants in whom CKD status could not be ascertained at baseline, and these participants were excluded from these analyses. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, N.C., USA) or the R Statistical Computing Environment.

Results

There were 9,308 SPRINT participants in whom CKD status at baseline was determined. The mean age was 67.9 ± 9.4 years; 65% were men. Racial and ethnic composition included approximately 30% black and 10% Hispanic. Subgroups at baseline included 28.4% with CKD (eGFR_{MDRD} <60 ml/min/1.73 m²), 28.1% aged ≥ 75 years and 20.1% who had prior CVD. Overall, the median (25th–75th percentile) eGFR_{MDRD} was 71.2 ml/min/1.73 m² (58.1–84.4) and the median (25th–75th percentile) UACR was 9.5 mg/g (5.6–21.4).

Compared to the original classification of CKD by the MDRD equation, 1,027 participants (11.0%) were reclassified into a different CKD category using the CKD-EPI equation, including 681 participants (7.3%) who were reclassified to a less advanced CKD stage (higher eGFR) and 346 participants (3.7%) who were reclassified to a more advanced CKD stage (lower eGFR). Characteristics associated with a reclassification to a less advanced CKD stage, based on univariate analysis, included younger age, female sex, white race, lower FRS, higher low-density lipoprotein cholesterol level, lower high-density lipoprotein cholesterol level, higher diastolic BP, absence of prior cardiovascular history and lower urine protein or urine albumin excretion. Selected baseline characteristics of the SPRINT participants, according to reclassification status, are shown in table 1.

More than 10% of participants with a baseline MDRD eGFR of ≥ 90 ml/min/1.73 m² were reclassified to a more advanced CKD stage when eGFR was calculated using the CKD-EPI equation (fig. 1). Conversely, 8.7, 11.2 and 5.1% of participants, respectively, with MDRD eGFRs of 60–89, 45–69 and 30–44 ml/min/1.73 m² were reclassified to a less advanced CKD stage when the CKD-EPI equation was employed. Age has a substantial impact on CKD reclassification in our cohort. For the age category of 50–64 years, 17.9, 25.6 and 11.5% of participants, respectively, with MDRD GFRs of 60–89, 45–69 and 30–44 ml/min/1.73 m² were reclassified to a less advanced stage of

CKD while the level of reclassification to a less advanced stage of CKD in the age category of ≥ 75 years was consistently $\leq 1.5\%$ (fig. 2). Conversely, for the age category of ≥ 75 years, 66.3, 5.6, 7.6 and 4.8% of participants, respectively, with MDRD GFRs of ≥ 90 , 60–89, 45–69 and 30–44 ml/min/1.73 m² were reclassified to a more advanced stage of CKD. Reclassification to a more advanced stage of CKD in the 50–64 years or older age group rarely occurred across all CKD categories.

Reclassification status based on race and sex is depicted in figure 3. Non-black men and women had similar patterns of reclassification, with 21–23% reclassification to a lower eGFR if the MDRD calculated eGFR was ≥ 90 ml/min/1.73 m² and higher rates of reclassification to higher levels of eGFR than to lower levels of eGFR at MDRD eGFRs ≤ 90 ml/min/1.73 m². A similar pattern was seen for Hispanics; however, there was a higher rate of reclassification to higher levels of eGFR than in whites. Black men and women had low levels of reclassification at eGFRs of ≥ 90 ml/min/1.73 m² and were less likely to be reclassified compared to non-blacks of the same sex at lower levels of MDRD eGFRs.

There were 2,742 (29.5%) participants who were classified as having CKD using either or both of the estimating equations for eGFR. This subgroup included 198 participants who had an MDRD eGFR <60 ml/min/1.73 m² and a CKD-EPI eGFR >60 ml/min/1.73 m² and 85 participants who had an MDRD eGFR >60 ml/min/1.73 m² and a CKD-EPI eGFR <60 ml/min/1.73 m² (table 2). Variables associated with reclassification of this subgroup were similar to that seen in the entire SPRINT cohort.

The agreement between eGFR categories using the 2 eGFR estimating equations, as determined by weighted kappa statistics (table 3), was also associated with subject characteristics, with lower levels of agreement seen in the 50–65 years age group, other races, Hispanic ethnicities and lower levels of albuminuria.

Discussion

In this large sample of non-diabetic individuals at increased risk of cardiovascular events including more than one in 4 with CKD, 7.3% of participants were reclassified to a less advanced CKD stage (higher eGFR) and 3.7% were reclassified to a more advanced CKD stage (lower eGFR) when the CKD-EPI equation was used to calculate eGFR. Age was the most important factor in reclassification. Participants <75 years of age more frequently had a

Table 1. Characteristics of SPRINT participants according to reclassification status

	Upward to less advanced CKD stage (higher eGFR) using CKD-EPI (n = 681)	No reclassification (n = 8,281)	Downward to more advanced CKD stage (lower eGFR) using CKD-EPI (n = 346)	p value
Age, years				<0.0001
50–<65	522 (76.7)	3,269 (39.5)	0 (0.0)	
65–<75	147 (21.6)	2,657 (32.1)	77 (22.3)	
≥75	12 (1.8)	2,355 (28.4)	269 (77.7)	
Sex				<0.0001
Male	382 (56.1)	5,369 (64.8)	255 (73.7)	
Female	299 (43.9)	2,912 (35.2)	91 (26.3)	
Race/ethnicity				<0.0001
White	423 (62.1)	4,740 (57.2)	213 (61.6)	
Black	115 (16.9)	2,568 (31.0)	100 (28.9)	
Hispanic	130 (19.1)	822 (9.9)	23 (6.6)	
Other	13 (1.9)	151 (1.8)	10 (2.9)	
Education, years				0.6324
<12	57 (8.4)	774 (9.3)	39 (11.3)	
12	111 (16.3)	1,343 (16.2)	61 (17.6)	
>12	513 (75.3)	6,162 (74.4)	246 (71.1)	
Unknown	0 (0.0)	2 (0.0)	0 (0.0)	
10-Year, FRS, %	13.52 (9.75–19.24)	17.93 (12.1–25.68)	26.28 (17.32–34.91)	<0.0001
FRS >15%	298 (43.9)	5,143 (62.3)	286 (82.9)	<0.0001
LDL cholesterol, mg/dl	118.79±36.93	112.23±35.02	103.7±30.56	<0.0001
HDL cholesterol, mg/dl	50.79±13.98	52.89±14.47	56.19±14.64	<0.0001
Systolic BP, mm Hg	138.91±16	139.64±15.53	141.61±15.75	0.0307
Diastolic BP, mm Hg	81.73±11.16	78.13±11.92	71.03±10.81	<0.0001
History of CVD	125 (18.4)	1,660 (20.0)	82 (23.7)	0.1292
Previous MI, CABG, PCI, carotid endarterectomy or carotid stenting	87 (12.8)	1,119 (13.5)	68 (19.7)	0.0039
PAD with revascularization	6 (0.9)	121 (1.5)	1 (0.3)	0.0991
Acute coronary syndrome with or without resting ECG changes, ECG changes on graded exercise test or positive cardiac imaging study	30 (4.4)	399 (4.8)	13 (3.8)	0.6698
50% stenosis of a coronary, carotid or lower extremity artery	23 (3.4)	260 (3.1)	13 (3.8)	0.6974
AAA ≥5cm with or without repair	2 (0.3)	57 (0.7)	2 (0.6)	0.5461
Coronary artery calcium score ≥400 Agatston units	4 (0.6)	23 (0.3)	0 (0)	0.2602
Low ABI (≤0.90)	4 (0.6)	44 (0.5)	4 (1.2)	0.2587
LVH by computer ECG reading, echogram report or other cardiac imaging procedure	35 (5.1)	385 (4.6)	11 (3.2)	0.3698
UACR, mg/g	7.94 (5.15–14.66)	9.52 (5.62–21.67)	14.29 (7.77–35.06)	<0.0001
Albuminuria, mg/g				<0.0001
Unknown	38 (5.6)	373 (4.5)	11 (3.2)	
<30	556 (81.6)	6,363 (76.8)	244 (70.5)	
30–<300	78 (11.5)	1,322 (16)	75 (21.7)	
≥300	9 (1.3)	223 (2.7)	16 (4.6)	
Urine microalbumin, mg/l	10 (5–19)	11 (6–25)	13 (7–31.75)	<0.0001

Values are n (%), mean ± SD, or median (interquartile range).

LDL = Low-density lipoprotein; HDL = high-density lipoprotein; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; PAD = peripheral artery disease; AAA = abdominal aortic aneurysm; ABI = ankle brachial index; LVH = left ventricular hypertrophy.

Fig. 1. Reclassification rates for SPRINT participants ($n = 9,308$) across eGFR categories by the CKD-EPI and MDRD study equations. Blue bars indicate reclassification to less advanced CKD stage (higher eGFR); yellow bars, no reclassification; red bars, downward reclassification to more advanced CKD stage (lower eGFR).

higher eGFR using the CKD-EPI equation, while participants aged ≥ 75 years more frequently had a lower eGFR using the CKD-EPI equation. The highest agreement between eGFR equations was seen among black participants, and this group had the lowest frequency of eGFR reclassification. Reclassification resulting in a change in (dichotomous) baseline CKD status (<60 ml/min/1.73 m²) was observed in 3% of participants.

There are several limitations to the use of either the MDRD equation or the CKD-EPI equation for the estimation of GFR. First, it is important to consider the populations studied for the validation of these 2 estimating equations. The MDRD equation was validated in 1,085 patients with an eGFR of <60 ml/min/1.73 m² who did not have either insulin-requiring diabetes mellitus or a body weight $>160\%$ standard body weight [2].

The MDRD cohort was younger than the SPRINT cohort, with a mean age of 51 ± 13 years and only included participants with CKD. A subsequent validation study was conducted in 5,504 individuals who were younger than those in the SPRINT cohort, with a mean age of 47 ± 13 years [16]. The development and validation of the

CKD-EPI equation included participants who were younger than those in the SPRINT cohort, with mean ages of 47 ± 15 and 50 ± 15 years, respectively [2]. In fact, a minority of the individuals used in either sample were ≥ 70 years.

Second, other investigators have compared both estimating equations to other more formal measures of GFR and have found that the CKD-EPI equation has greater precision and accuracy. Earley et al. [11] performed a systematic review of studies that compared a reference GFR method with both the MDRD and CKD-EPI eGFR equations. For the 12 studies conducted in North America, Europe and Australia, the CKD-EPI equation performed better at higher GFRs (approximately >60 ml/min/1.73 m²) while the MDRD equation performed better at lower GFRs. For the 8 studies conducted in Asian or black populations, which used a modified MDRD equation to improve performance in the local population, neither equation performed as well as they did in North American or European populations. The large study ($n = 5,238$) of Murata et al. [17] observed that, compared to a gold standard ¹²⁵I-iothalamate measured GFR, both estimat-

Fig. 2. Reclassification rates for SPRINT participants by age across eGFR categories by the CKD-EPI and MDRD study equations. Blue bars indicate reclassification to less advanced CKD stage (higher eGFR); yellow bars, no reclassification; red bars, downward reclassification to more advanced CKD stage (lower eGFR).

Fig. 3. Reclassification rates for SPRINT participants by race (black or white only) Hispanic ethnicity and gender across eGFR categories by the CKD-EPI and MDRD study equations. Blue bars indicate reclassification to less advanced CKD stage (higher eGFR); yellow bars, no reclassification; red bars, downward reclassification to more advanced CKD stage (lower eGFR).

Table 2. Reclassification of SPRINT participants with eGFR <60 ml/min/1.73 m² based on either MDRD or CKD-EPI study equations

	eGFR, ml/min/1.73 m ²			p value
	eGFR _{MDRD} <60, eGFR _{CKD-EPI} ≥60 (n = 198)	eGFR _{MDRD} <60, eGFR _{CKD-EPI} <60 (n = 2,459)	eGFR _{MDRD} ≥60, eGFR _{CKD-EPI} <60 (n = 85)	
Age, years				<0.0001
50–<65	111 (56.1)	539 (21.9)	0 (0)	
65–<75	76 (38.4)	759 (30.9)	14 (16.5)	
≥75	11 (5.6)	1,161 (47.2)	71 (83.5)	
Sex				0.0033
Male	103 (52.0)	1,490 (60.6)	62 (72.9)	
Female	95 (48.0)	969 (39.4)	23 (27.1)	
Race/ethnicity				<0.0001
White	153 (77.3)	1,625 (66.1)	39 (45.9)	
Black	16 (8.1)	621 (25.3)	43 (50.6)	
Hispanic	26 (13.1)	175 (7.1)	3 (3.5)	
Other	3 (1.5)	38 (1.5)	0 (0.0)	
Education, years				0.0223
<12	15 (7.6)	280 (11.4)	11 (12.9)	
12	22 (11.1)	437 (17.8)	11 (12.9)	
>12	161 (81.3)	1,742 (70.8)	63 (74.1)	
10-Year, FRS, %	14.21 (9.81–19.89)	19.52 (12.64–28.6)	27.55 (19.34–33.99)	<0.0001
FRS >15%	91 (46.2)	1,617 (65.9)	72 (85.7)	<0.0001
LDL cholesterol, mg/dl	117.7±32.5	106.68±34.3	105.46±29.88	<0.0001
HDL cholesterol, mg/dl	51.28±14.68	52.76±14.72	55.04±13.9	0.1332
Systolic BP, mm Hg	136.91±15.47	139.35±16.12	139.57±14.95	0.1187
Diastolic BP, mm Hg	79.03±11.18	74.63±12.24	71.44±11.44	<0.0001
History of CVD	31 (15.7)	615 (25.0)	15 (17.6)	0.0046
Previous MI, CABG, PCI, carotid endarterectomy or carotid stenting	25 (12.6)	445 (18.1)	10 (11.8)	0.0550
PAD with revascularization	2 (1.0)	46 (1.9)	1 (1.2)	0.8576
Acute coronary syndrome with or without resting ECG changes, ECG changes on a graded exercise test or positive cardiac imaging study	8 (4)	145 (5.9)	4 (4.7)	0.5707
50% stenosis of a coronary, carotid or lower extremity artery	8 (4)	94 (3.8)	2 (2.4)	0.8661
AAA ≥5 cm with or without repair	1 (0.5)	24 (1.0)	0 (0.0)	1.0000
Coronary artery calcium score ≥400 Agatston units	1 (0.5)	11 (0.4)	0 (0.0)	0.7298
Low ABI (≤0.90)	2 (1)	16 (0.7)	0 (0.0)	0.7947
LVH by computer ECG reading, echogram report or other cardiac imaging procedure	9 (4.5)	115 (4.7)	3 (3.5)	0.9705
UACR, mg/g	8.1 (5.07–18.66)	13.92 (6.52–46.01)	14.29 (6.9–30.43)	<0.0001
Albuminuria, mg/g				0.0003
Unknown	9 (4.5)	83 (3.4)	0 (0.0)	
<30	154 (77.8)	1,592 (64.7)	63 (74.1)	
30–<300	31 (15.7)	618 (25.1)	17 (20.0)	
≥300	4 (2.0)	166 (6.8)	5 (5.9)	
Urine microalbumin, mg/l	10 (5–26)	15 (7–49)	13 (8–37)	<0.0001

Values are n (%), mean ± SD, or median (interquartile range). LDL = Low-density lipoprotein; HDL = high-density lipoprotein; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; PAD = peripheral artery disease; AAA = abdominal aortic aneurysm; ABI = ankle brachial index; LVH = left ventricular hypertrophy.

ing equations overestimated GFR in individuals >70 years of age who had CKD (9% for MDRD eGFR vs. 5% for CKD-EPI) and underestimated GFR in younger healthy individuals (–17% for MDRD eGFR vs. –9% for CKD-EPI). In a study of 392 elderly individuals who were at

least 74 years of age, Kilbride et al. [5] measured GFR by the iothexol clearance method and found that the CKD-EPI equation appeared less biased and was more accurate than the MDRD equation. Both equations overestimated measured GFR; however, this was only significant for the

Table 3. Agreement between eGFR categories by the CKD-EPI and MDRD study equations

	Number	Kappa statistic (95% CI)	
		unweighted	weighted ^a
Age, years			
50–<65	3,791	0.77 (0.76–0.79)	0.90 (0.89–0.91)
65–<75	2,881	0.87 (0.85–0.89)	0.94 (0.93–0.95)
≥75	2,636	0.84 (0.82–0.85)	0.93 (0.93–0.94)
Sex			
Male	6,006	0.83 (0.82–0.84)	0.93 (0.92–0.93)
Female	3,302	0.82 (0.80–0.84)	0.93 (0.93–0.94)
Race/ethnicity			
White	5,376	0.81 (0.79–0.82)	0.92 (0.91–0.93)
Black	2,783	0.88 (0.87–0.90)	0.96 (0.95–0.96)
Hispanic	975	0.75 (0.71–0.78)	0.90 (0.88–0.92)
Other	174	0.78 (0.70–0.87)	0.89 (0.85–0.94)
Race/ethnicity and sex			
White female	1,540	0.80 (0.77–0.82)	0.92 (0.90–0.93)
White male	3,836	0.81 (0.80–0.83)	0.92 (0.91–0.93)
Black female	1,258	0.88 (0.86–0.90)	0.96 (0.95–0.97)
Black male	1,525	0.89 (0.86–0.91)	0.95 (0.94–0.96)
Hispanic female	449	0.71 (0.65–0.77)	0.88 (0.85–0.92)
Hispanic male	526	0.78 (0.73–0.82)	0.91 (0.89–0.93)
FRS >15%			
No	3,553	0.81 (0.79–0.82)	0.93 (0.92–0.93)
Yes	5,727	0.84 (0.83–0.85)	0.93 (0.93–0.94)
History of CVD			
No	7,441	0.83 (0.81–0.84)	0.93 (0.92–0.93)
Yes	1,867	0.83 (0.81–0.85)	0.94 (0.93–0.94)
Albuminuria, mg/g			
Unknown	422	0.80 (0.74–0.85)	0.89 (0.86–0.92)
<30	7,163	0.82 (0.80–0.83)	0.91 (0.91–0.92)
30–<300	1,475	0.86 (0.83–0.88)	0.95 (0.95–0.96)
≥300	248	0.87 (0.82–0.92)	0.96 (0.95–0.98)

^a Weighted kappa statistic computed using Fleiss–Cohen weights.

MDRD equation when the measured GFR was ≥ 60 ml/min/1.73 m². This effect was most pronounced for individuals aged ≥ 80 years.

Third, large retrospective meta-analyses have also demonstrated that use of the CKD-EPI equation improved risk stratification compared to the MDRD equation. Matsushita et al. [10] examined 1,010,988 participants in the Alberta, Canada, laboratory registry in whom outcome data were available for all-cause mortality, acute MI, ESKD and a doubling of the serum creatinine concentration. When the CKD-EPI equation was used instead of the MDRD equation, 22.6% of all participants (mean age 43.1 ± 11.8 years) were reclassified to a less advanced CKD stage. Conversely, the use of the CKD-EPI equation reclassified 1.2% of all par-

ticipants (mean age 81.1 ± 6.8 years) to a more advanced CKD stage. The reported prevalence of CKD stages 3 and 4 changed from 9.2 to 7.3%. Similarly, data from the Third National Health and Nutrition Examination Survey showed that use of the CKD-EPI equation resulted in 26.9% of the population being reclassified to a less advanced CKD stage and 2.2% being reclassified to a more advanced CKD stage. Characteristics associated with being reclassified to a less advanced CKD stage included younger age, female sex and lower prevalence of CVD and diabetes mellitus [7]. Finally, a meta-analysis of 45 studies comprising 1,130,472 adults, including those from the general population, those with CKD and those at risk for CKD determined that 24.4% of participants from the general population cohort were

reclassified to a less advanced CKD stage when the MDRD eGFR equation was replaced by the CKD-EPI equation, while 0.6% were reclassified to a more advanced CKD stage. This reclassification resulted in a decrease in the percentage of participants having stages 3–4 CKD from 8.7 to 6.3%. In the eGFR category of 45–59 ml/min/1.73 m², as determined by the MDRD equation, 34.7% of participants were reclassified to less advanced CKD by the CKD-EPI equation and these reclassified participants had lower levels of events (all-cause and cardiovascular mortality or ESKD) compared to participants who were not reclassified [9]. In all 3 studies, reclassification of CKD with the CKD-EPI equation improved risk stratification; in the latter study, this improvement was noted in multiple subgroups including elderly (≥65 years) versus non-elderly, sex, race and the presence or absence of hypertension and diabetes mellitus.

The strengths of this study include a large, racially diverse population that includes 30% blacks and 10% Hispanics as well as measurement of serum creatinine in a central laboratory using a method that has been standardized using a standardized and validated IDMS method. The findings from this study are limited by the lack of a measured GFR as a comparator. Results should be taken in the context of the study population in SPRINT; there may be more or less reclassification in other populations such as in patients with diabetes mellitus.

In conclusion, use of the MDRD equation led to a higher proportion of SPRINT participants being classified as having CKD stages 3–4. Participants who were younger or non-black were more likely to be reclassified as not having CKD when considering the CKD-EPI equation as the criterion standard.

Acknowledgments

The investigators would like to acknowledge the SPRINT participants without whom this trial would not have been possible. We also acknowledge the study staff in the 102 clinics in the SPRINT trial.

The SPRINT is funded with federal funds from the NIH, including the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging and the National Institute of Neurological Disorders and Stroke under contract numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, and inter-agency agreement number A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Vet-

erans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs or the United States Government. For a full list of contributors to SPRINT, see the online supplementary acknowledgement list (see www.karger.com/doi/10.1159/000448722): ClinicalTrials.gov identifier: NCT01206062.

We also acknowledge the support from the following CTSAAs funded by NCATS: CWRU: UL1TR000439, OSU: UL1RR025755, UPenn: UL1RR024134 and UL1TR000003, Boston: UL1RR025771, Stanford: UL1TR000093, Tufts: UL1RR025752, UL1TR000073 and UL1TR001064, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, UT Southwestern: 9U54TR000017-06, University of Utah: UL1TR000105-05, Vanderbilt University: UL1TR000445, George Washington University: UL1TR000075, University of CA, Davis: UL1TR000002, University of Florida: UL1TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM103337 COBRE Award NIGMS.

The authors also acknowledge Dr. Jeffrey A. Cutler's role in the initial consideration of this trial concept during 2003–2007, which led to the subsequent sponsorship of SPRINT by NHLBI.

Support and Financial Disclosure Declaration

A.C. was a consultant for Kadmon, Otsuka. C.E.L. had research funding (paid to the institution) from Novo Nordisk. All other authors have no relevant disclosures.

References

- 1 Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK: The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the systolic blood pressure intervention trial (SPRINT). *Clin Trials* 2014;11:532–546.
- 2 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. *Ann Intern Med* 1999;130:461–470.
- 3 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–612.

- 4 Flamant M, Haymann JP, Vidal-Petiot E, Le-tavernier E, Clerici C, Boffa JJ, Vrtovsnik F: GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly. *Am J Kidney Dis* 2012;60:847–849.
- 5 Kilbride HS, Stevens PE, Eaglestone G, Knight S, Carter JL, Delaney MP, Farmer CK, Irving J, O’Riordan SE, Dalton RN, Lamb EJ: Accuracy of the MDRD (modification of diet in renal disease) study and CKD-EPI (CKD epidemiology collaboration) equations for estimation of GFR in the elderly. *Am J Kidney Dis* 2013;61:57–66.
- 6 Lewis JR, Lim W, Dhaliwal SS, Zhu K, Lim EM, Thompson PL, Prince RL: Estimated glomerular filtration rate as an independent predictor of atherosclerotic vascular disease in older women. *BMC Nephrol* 2012;13:58.
- 7 Shafi T, Matsushita K, Selvin E, Sang Y, Astor BC, Inker LA, Coresh J: Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III). *BMC Nephrol* 2012;13:42.
- 8 Shafi T, Parekh RS, Jaar BG, Plantinga LC, Oberai PC, Eckfeldt JH, Levey AS, Powe NR, Coresh J: Serum β -trace protein and risk of mortality in incident hemodialysis patients. *Clin J Am Soc Nephrol* 2012;7:1435–1445.
- 9 Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warrnack DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS: Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. *JAMA* 2012;307:1941–1951.
- 10 Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR: Clinical risk implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the modification of diet in renal disease (MDRD) study equation for estimated GFR. *Am J Kidney Dis* 2012;60:241–249.
- 11 Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K: Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. *Ann Intern Med* 2012;156:785–795; W270–W278.
- 12 Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT: A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 2015;373:2103–2116.
- 13 D’Agostino RB Sr, Vasan RS, Pencina MJ, et al: General cardiovascular risk profile for use in primary care: the Framingham heart study. *Circulation* 2008;117:743–753.
- 14 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Inter Suppl* 2013;3:1–150.
- 15 Fleiss JL, Cohen J, Everitt BS: Large sample standard errors of kappa and weighted kappa. *Psychol Bull* 1969;72:323–327.
- 16 Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS: Evaluation of the modification of diet in renal disease study equation in a large diverse population. *J Am Soc Nephrol* 2007;18:2749–2757.
- 17 Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC: Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. *Clin J Am Soc Nephrol* 2011;6:1963–1972.